Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Accelrys Slide 5 Percent on Flat Q4 Sales, Wider Losses

NEW YORK (GenomeWeb News) — Shares in Accelrys were down 5.3 percent, or $.35, at $6.21 in mid-afternoon trading after the company today posted weak fourth-quarter revenue growth and widened net loss.
As GenomeWeb News reported this morning, Accelrys said that total receipts for the three months ended Dec. 31, 2006, increased to $20.7 million from $20.4 million year over year. Losses nearly doubled to $1.1 million from $567,000 year over year.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.